Former Merrimack Pharma Exec Richard Peters to Join Yumanity as CEO

Yumanity Therapeutics has appointed Richard Peters to serve as its CEO. He is also joining the Cambridge, MA, company’s board of directors. Peters recently resigned as president and CEO of Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]), which has been selling assets in the wake of clinical trial setbacks. Prior to working at Merrimack, Peters was an executive in the Genzyme unit of Sanofi (NASDAQ: [[ticker:SNY]]). Yumanity is developing drugs to treat neurodegenerative disorders caused by misfolded proteins. Peters will start at the company on Sept. 3.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.